Tenpoint Therapeutics has submitted a UK regulatory application for YUVEZZI, a once-daily eye drop combining carbachol and brimonidine tartrate to restore near vision in presbyopia. Phase 3 data demonstrated sustained improvement in near vision with a safety profile supporting long-term use in a condition affecting approximately 2 billion adults globally.
Key Points
- Once-daily dual-agent formulation produces near vision improvement lasting 30 minutes to 10 hours
- Phase 3 trials showed no treatment-related serious adverse events over 12 months and 72,000 dosing d
- Addresses presbyopia affecting 2 billion adults; reduces dependence on progressive lens correction
Longevity Analysis
Presbyopia represents a functional decline in accommodation that accelerates visual system aging and constrains quality of life across professional and daily tasks. Pharmacological restoration of near vision through pupillary constriction and enhanced lens focusing extends the functional window of the visual apparatus without requiring surgical intervention. For aging populations, preservation of unaided near vision directly supports cognitive engagement, fine motor tasks, and the sensory feedback loops that maintain neurological reserve and postural stability.
Original published by Longevity.Technology.